European Commission Breaks With CHMP on AMT's Glybera

LONDON – There's been another twist in the gene therapy saga, with the European Commission refusing to give its usual rubber stamp to the European Medicines Agency's (EMA) decision not to grant marketing authorization to Glybera, a treatment for inherited disorder lipoprotein lipase deficiency (LPL).

To continue reading subscribe now to BioWorld Asia (formerly International)